Therefore, HCC patients with transarterial chemoembolization (TACE) resistance and high serum SPINK1 levels could potentially benefit from monoclonal SPINK1 neutralizing antibodies to sensitize cells to TACE and improve the overall treatment response. The gene discussed is SPINK1; the disease is hepatocellular carcinoma.